Cancer Survivor's Breath Device Detects Lung Cancer Early

Imagine detecting lung cancer with a single breath into a device that fits in your pocket. That breakthrough is now closer than ever, thanks to a team at Vocxi Health who spent eight years perfecting a technology that could save millions of lives.

The MyBreathPrint device looks simple but represents a massive leap forward in cancer detection. Patients breathe into it for just one minute, and graphene nanosensors immediately detect volatile organic compounds that signal the presence of cancer, even before symptoms appear.

CEO Ping Yeh knows personally why this matters. The blood cancer survivor has been in remission for 12 years and joined Vocxi in 2022 with a mission to make early detection accessible to everyone. "Our vision is to make the easiest and earliest detection platform that the world's ever seen," Yeh said.

The secret lies in what the team did with graphene. They spent years developing special chemistries to coat the sensors, allowing them to detect specific compounds in breath that correspond with diseases. The technology measures capacitance at incredibly tiny levels, requiring custom designs to eliminate any electronic noise that could interfere with readings.

Getting the device small enough was another challenge. The original prototype was the size of an old Nintendo console. Working with partners at Forj Medical and S3 Connected Health, the team ran over 1,500 custom tests to shrink it down and eliminate interference while maintaining accuracy.

The device also had to handle the 90% humidity in human breath without producing false readings. Engineers developed new ways to control breath flow through the device, ensuring accurate results every time.

The Ripple Effect

While Vocxi is starting with lung cancer, the technology could expand to detect many other diseases. The company already has an ongoing ovarian cancer study at the University of Minnesota and has won grants to investigate two additional conditions. The same sensor platform and chemistry library could potentially screen for multiple cancers with a single breath.

The team plans to launch a pivotal trial after their current clinical pilot concludes in mid-2026. They've already met with the FDA twice about potential Breakthrough Device designation, which could fast-track approval for this life-saving technology.

Finding cancer before symptoms appear could transform survival rates. Yeh notes that treating stage four cancer costs at least seven times more than treating early-stage disease, making this device potentially game-changing for both patients and healthcare systems.

The Minneapolis-area team credits strong partnerships for their success, building trust through frequent in-person meetings and maintaining a decision log to keep development moving forward. Their collaboration shows what's possible when innovation meets determination.

A simple breath test could soon give millions of people the gift of early detection and better odds of beating cancer.